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Abstract
Background: The R620W variant in protein tyrosine phosphatase non-receptor 22 (PTPN22) is associated with
rheumatoid arthritis (RA). The PTPN22 gene has alternatively spliced transcripts and at least two of the splice forms
have been confirmed to encode different PTPN22 (LYP) proteins, but detailed information regarding expression of
these is lacking, especially with regard to autoimmune diseases.
Methods: We have investigated the mRNA expression of known PTPN22 splice forms with TaqMan real-time PCR
in relation to ZNF592 as an endogenous reference in peripheral blood cells from three independent cohorts with
RA patients (n = 139) and controls (n = 111) of Caucasian origin. Polymorphisms in the PTPN22 locus (25 SNPs) and
phenotypic data (gender, disease activity, ACPA and RF status) were used for analysis. Additionally, we addressed
possible effects of methotrexate treatment on PTPN22 expression.
Results: We found consistent differences in the expression of the PTPN22 splice forms in unstimulated peripheral
blood mononuclear cells between RA patients and normal controls. This difference was more pronounced when
comparing the ratio of splice forms and was not affected by methotrexate treatment.
Conclusions: Our data show that RA patients and healthy controls have a shift in balance of expression of splice
forms derived from the PTPN22 gene. This balance seems not to be caused by treatment and may be of
importance during immune response due to great structural differences in the encoded PTPN22 proteins.
Background
It is well established that rheumatoid arthritis (RA) is a
heritable disease with a substantial genetic influence on
the outcome. PTPN22 is one of the few undisputed
genetic risk factors for RA that has been replicated in
many Caucasian populations, and evidence for its being a
true susceptibility gene is strong [1,2]. Since the discovery
of the importance of PTPN22 in the function of lympho-
cytes [3,4], and especially after its association with differ-
ent autoimmune diseases [1], several attempts have been
made to explain the biological mechanism of how
PTPN22 gene variants may influence protein activity and
subsequent differences in cell function. The best-asso-
ciated polymorphism, rs2476601, which affects amino
acid 620, is an R to W missense polymorphism that may
alter the function of the protein. Many studies have
focused on this change of function and have indeed
found evidence for immune regulatory effects, suggesting
that cells with the disease-associated allele may have a
gain of function for PTPN22 resulting in stronger nega-
tive regulation of T-cell activation [5] and B-cell activa-
tion [6]. There is, however, evidence for other common
genetic variants in the locus that associate with disease
independently of rs2476601 [7], although the indepen-
dent effect has been questioned [8], and recently another
missense variant at amino acid 263, rs33996649 (an R to
Q polymorphism) has been associated with RA [9]. Also,
a genetic interaction was previously described between
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epitope (SE) alleles [10,11]. Even though multiple roles
for PTPN22 have been discovered, we are far from
understanding the specific mechanism involved in the
development of autoimmunity in general and, more spe-
cifically, of RA.
The PTPN22 gene (MIM ID *600716) encodes an 807
amino acid protein called lymphoid tyrosine phosphatase
(LYP), which belongs to the proline-, glutamic acid-, ser-
ine-, and threonine-rich (PEST) group of non-receptor
classical class I protein tyrosine phosphatases. PTPN22
expresses several splice forms, but there is surprisingly
little known about the function and regulation of these.
At least two of them are translated into proteins [3],
LYP1 (designated here as PTPN22_v1) and LYP2 (desig-
nated here as PTPN22_v4) (see Figure S1 in Additional
file 1 for a demonstration of LYP expression in several
cell lines). LYP1 contains an amino-terminal PTP
domain, a central region of unknown function, and a car-
boxy-terminal portion (approximately 200 amino acids)
containing four proline-rich motifs termed P1 to P4. The
alternatively spliced LYP2 has a shorter carboxyl termi-
nus, resulting in the absence of the P2, P3, and P4 motifs
[12].
We aim to describe the variance in the expression of
t h es p l i c ef o r m so fPTPN22 in peripheral blood mono-
nuclear cells (PBMCs) in individuals with RA and in
healthy controls and in relation to genotype data from
this locus and to other RA risk factors. Since the struc-
ture and, possibly, the function of these splice forms is
different, this may reveal important regulatory effects of
disease-associated alleles.
Materials and methods
Transcript identifiers for well established splice forms of
PTPN22
The RefSeq accession [3,13] transcript identifiers for well
established splice forms of PTPN22 are: PTPN22_v1
(LYP1), National Center for Biotechnology Information
(NCBI) accession [NM_015967.5]; PTPN22_v4 (LYP2),
NCBI accession [NM_012411.3]; PTPN22_v3 (LYP3),
NCBI accession [NM_001193431.1]; and PTPN22_v2,
NCBI accession [NM_012411.4].
Patients and controls
This study includes four cohorts of individuals; cohort
population characteristics can be found in Table S1 in
Additional file 2. In short, cohort I includes 44 RA
patients and 44 controls from Sweden; cohort II
includes 47 RA patients and 19 controls from Sweden;
cohort III includes 48 RA patients and 48 controls from
the US; and cohort IV includes 60 multiple sclerosis
(MS) patients from the same geographical area as
cohorts I and II. The controls for all cohorts were
selected with consideration to gender, age and ethnicity
for each patient group. All four cohorts are completely
independent. RA patients in cohorts I and II were
selected at the rheumatology clinic of the Karolinska
University Hospital on two occasions and all correspond
to American College of Rheumatology 1987 criteria for
rheumatoid arthritis [14]. RA patients in cohort III were
aged between 41 and 76 years and had a clinical diagno-
sis of active disease for at least 6 months, with a mini-
mum age of onset of 16 years. All were on a stable dose
of methotrexate for at least 12 weeks. Subjects with any
significant health problem other than RA or non-RA
related laboratory abnormalities were not included. The
48 controls, 34 females and 14 males, were selected to
match the RA patients and had the same number of
subjects per age group, with the age groups defined as
41 to 50, 51 to 60, 61 to 70, and over 71 years. All were
confirmed to have normal hematologic, renal, and hepa-
tic functions as determined by laboratory test results.
Information about anti-citrullinated protein antibody
(ACPA) status, smoking habits and medication (for RA
patients) were obtained from medical records for cohort
I. Peripheral blood cell samples from MS patients in
cohort IV were selected from an in-house biobank (Neu-
rology Clinic, Karolinska University Hospital) containing
specimens collected from individuals during routine neu-
rological diagnostic work-up. The additional three con-
trols for the methotrexate experiment were healthy
volunteers not taking any ongoing medication.
Informed consent was obtained from all participants
in all cohorts, in compliance with the latest version of
the Helsinki Declaration. Regional ethical committees at
all sites have approved the study.
Genotyping
Genotyping for the locus in cohort I was performed by
Illumina 300 K chip in our previous genome-wide asso-
ciation study (GWAS) and we employed a linkage dise-
quilibrium map for the PTPN22 locus from genotyping
of 3,000 RA cases and controls [15]. Additionally, we per-
formed genotyping of rs2476601 for cohort I (which was
in full agreement with data from the GWAS [15] and
rs3789607 for cohort II using a TaqMan allelic discrimi-
nation assay. HLA DRB1 data were obtained and reported
for this cohort previously [16].
Cell culture and RNA extraction
The cell purification protocol and RNA extraction for
cohorts I and IV and the additional three controls for
the methotrexate experiment were described previously
[17]. Briefly, sodium citrate vacuum tubes (Vacutainer,
Becton-Dickinson, Franklin Lakes, NJ, USA) were used
for collecting blood according to the protocol from the
manufacturer. PBMCs were cleaned with PBS and spun
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for viable cell counting. Cells were then spun down for
10 minutes and resuspended in DMEM (Sigma, Stein-
hem, Germany) and 5 ×10
5 cells were used for the fol-
lowing cell cultivations. For cohort I, IFNg,5 0U
(Preprotech, London, UK) or corresponding volume of
medium was added in cell cultures and cells were incu-
bated for 6 h at 37°C. For the methotrexate experiment,
cells were incubated in RPMI-1640 (Sigma, Ayrshire,
UK) at a final concentration of 0, 1, 10, 100 or 1,000
μM methotrexate (Wyeth Lederle Nordiska AB, Solna,
Sweden) for 24 h at 37°C. After incubation (cohort IV
was unstimulated) cells were lysed with RLT buffer
from the mini RNA prep kit and subsequently RNA
extracted (RNeasy Mini, Qiagen, Hilden, Germany). For
cohort II, peripheral blood was taken in PAX tubes fol-
lowed by RNA extraction with the PAXgene Blood RNA
kit according to the manufacturer’s protocol (PreAnaly-
tiX, Hombrechtikon, Switzerland). mRNA from cohort I,
II and IV samples was stored at -80°C prior to cDNA
synthesis, which was performed with an iScript cDNA
synthesis kit following the manufacturer’sp r o t o c o l
(BioRad, Hercules, CA, USA).
For cohort III, PBMCs were isolated from whole blood
samples collected into cell purification tubes (Becton
Dickinson) according to the manufacturer’s recommen-
dations. All samples were shipped at room temperature
in a temperature-controlled box overnight from the col-
lection site to the laboratory, cell differential counts
taken, PBMCs purified according to the CPT manufac-
turer’s instructions and cell pellets stored at -80°C pend-
ing RNA purification. RLT lysis buffer (with 1% (10 μl
in 1 ml) b-mercaptoethanol) was added to frozen pellets,
RNA isolated using an RNeasy Mini kit (Qiagen) and
DNase treatment performedu s i n gt h eQ i a g e nR N a s e -
free DNase kit. Phenol:chloroform (1:1) extraction was
performed subsequently, and RNA was re-purified using
the RNeasy Mini kit. Eluted RNA was quantified using a
ND-1000 Spectrophotometer (Nanodrop, Wilmington,
DE, USA). RNA was converted to cDNA using the
Applied Biosystems High Capacity cDNA Archive kit
with RNase inhibitor at 50 U/sample (Applied Biosys-
tems, Foster City, CA, USA). cDNA samples were stored
at -20°C pending TaqMan
® assay.
The Jurkat and Daudi cell lines were seeded at a con-
centration of 4 × 10
5/ml in RPMI-1640 medium (Sigma,
Ayrshire, UK)) with 10% fetal bovine serum (Gibco,
Invitrogen, Stockholm, Sweden) at 37°C. After 12 h, 1.6
×1 0
6 cells were used for incubation with methotrexate
for 24 h at 37°C. The same procedure as for cohort I
was followed for the subsequent handling. Description
of cell lines and methods for Western blot can be found
in Additional file 3.
Cytotoxicity measurement
The cytotoxic effect of methotrexate treatment of
PBMCs and cell lines was estimated using a cytotoxicity
detection kit (LDH; Roche, Mannheim, Germany). The
procedure was performed according to manufacturer’s
recommendation.
Quantitative PCR
For this study we used TaqMan assays from Applied Bio-
systems to interrogate the splice forms for PTPN22.A tt h e
time the study was done, the assays available were
Hs00247352_m1 and Hs00249262_m1. Hs00247352_m1
is specific for the short splice form PTPN22_v4/LYP2,
while the latter detects the long splice form PTNP22_v1/
LYP1. This assay will also detect the recently reported
splice form PTPN22_v3/LYP3 [13] as well as the recently
u p d a t e dR e f s e qi s o f o r mPTPN22_v2. We refer to these
t h r e es p l i c ef o r m s ,PTPN22_v1, PTPN22_v2 and
PTPN22_v3, as PTPN22-long isoforms. Hs00206029_m1
was used for the endogenous reference gene ZNF592.
ZNF592 was selected as a normalizer gene based on a sur-
vey of oligonucleotide array expression data for 44,928
transcripts across a compendium of 9,270 hybridizations,
including multiple studies involving different types of cells
and tissues. In this broad survey, ZNF592 had substantially
less variability than other commonly utilized endogenous
controls. Specifically, it had a coefficient of variation that
was at the 0.01th percentile of variation among all sur-
veyed transcripts (Table S2 in Additional file 2). Consis-
tent with this finding, other groups have independently
characterized ZNF592 as a ubiquitously expressed tran-
script in a panel of 24 adult human tissues by semi-quanti-
tative PCR and northern blotting [18]. Expression
measurements were made using the delta-delta relative
quantification method according to the Applied Biosys-
tems protocol. The mean delta Ct values for controls were
used as calibrator. For cohort I each sample was measured
six times, and for cohorts II and IV it was done in dupli-
cates, and average values were calculated and used as rela-
tive measurements. For cohort III, RNA expression levels
in human PBMCs were measured by using the ABI
7900HT Sequence detector (Sequence Detector Software
2.2.3) according to manufacturer’s instructions. Relative
quantification values were calculated from ΔΔCt values
using the Sequence Detection System software, and
further analyzed in a Spotfire-guided application (Spotfire
Decision-Site 8™, TIBCO Software Inc. Somerville, MA,
USA) developed within the Pfizer Massachusetts Research
Business Technologies Department.
Statistics
For comparing differences between groups, we used the
non-parametric Mann-Whitney test and Kruskal-Wallis
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Bonferroni correction when necessary.
Results
Differential expression of PTPN22 splice forms in PBMCs
from healthy controls and patients with RA
To evaluate expression of the PTPN22 splice forms, we
measured the expression levels of PTPN22-long isoforms
and the short isoform PTPN22_v4 (LYP2; Figure 1), rela-
tive to ZNF592 expression in PBMCs of healthy indivi-
duals and RA patients (cohort I) after 6 h of cultivation of
cells without stimulation. For both assays, we detected a
difference in average expression between patients and con-
trols. For PTPN22_v4 we saw a reduction in expression
(0.85-fold decrease, non-significant) in RA cases and for
PTPN22-long isoforms an increase in expression for RA
cases (1.20-fold increase, P = 0.006) (Table 1).
Since we used two assays to measure every sample, we
could normalize the expression data by calculating a ratio.
This reflects the balance between productions (and stabi-
lity) of these splice forms for each individual and provides
a better measure for comparing individuals by reducing
the effect that the endogenous reference may have. By
comparing the ratio of expression (Figure 2), we found
that PTPN22 expression in RA cases is significantly differ-
ent compared with that in controls (P =6×1 0
-9), which is
a result of significantly higher expression of PTPN22-long
isoforms and simultaneously slightly lower expression of
PTPN22_v4 in patients (Table 1).
To replicate our findings, we measured expression of
the PTPN22 splice forms in two independent collections
of mRNA from whole blood from 19 controls and 47
RA patients from a Swedish population (cohort II) and
48 controls and 48 RA patients from the US (cohort
III). The difference in expression was significant for the
ratio of the transcripts (P =0 . 0 2a n dP = 0.01 for
cohorts II and III, respectively) and demonstrated a
similar trend for higher expression of PTPN22-long iso-
forms in cohort II and lower expression of PTPN22_v4
in cohort III (P =1 . 2×1 0
-4) for patients with RA
(Table 1).
IFNg-induced expression of PTPN22 splice forms in
healthy controls and patients with RA
To facilitate a mechanistic interpretation of differential
expression of PTPN22 splice forms, we also measured
PTPN22_v4, Lyp2 

Tyrosine phosphatase receptor domain  SH3 dom, Csk bind, P2 
CDK1 bind 
SH3 dom, P3 
CTH dom, SH3 dom, P4 
SH3, P1 
rs2476601 
Hs00247352_m1 
Hs00249262_m1  
PTPN22_v1, Lyp1 
PTPN22_v2 
PTPN22_v3 
5
Figure 1 Exonic-intronic structure of splice forms and domain representation of PTPN22. A genomic illustration of PTPN22 in human
chromosome 1p32. Hs00247352_m1 and Hs00249262_m1 are assay numbers (Applied Biosystems). The four SRC homology 3 (SH3) domains are
denoted by P1 to P4 and are typically involved in protein-protein interaction. Known binding sites for carboxy-terminal Src kinase (Csk) and CD2-
binding protein 1 (CD2BP1) are located in P2 and P4 (carboxy-terminal homology (CTH) domain), respectively. The carboxyl terminus of Lyp1
contains a consensus motif for cyclin-dependent kinase 1 (CDK1). The exonic and basic domain structure is deduced from Ensembl (Ensembl 64,
September 2011) [30] and UCSC Genome Browser (GRCh37/hg19 assembly) [31] and published articles [3,12].
Table 1 Expression of PTPN22 transcripts in peripheral
blood mononuclear cells from cohorts I, II and III
Median relative quantity values
Control group RA patient group P-value
a
Cohort I n =4 4 n =4 4
PTPN22_v4 1.05 0.85 0.08
PTPN22-long 1.03 1.20 0.006
long/v4
b 1.01 1.42 6 × 10
-9
Cohort II n =1 9 n =4 7
PTPN22_v4 0.98 0.96 0.85
PTPN22-long 0.97 1.07 0.25
long/v4
b 0.96 1.15 0.02
Cohort III n =4 8 n =4 8
PTPN22_v4 0.96 0.72 1.2 × 10
-4
PTPN22-long 0.97 0.92 0.2
long/v4
b 1.04 1.24 0.01
aP-value for comparison of rheumatoid arthritis (RA) patient group and control
group, Mann-Whitney test.
bThe ratio of PTPN22-long and PTPN22_v4 was
calculated for each sample separately.
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the same healthy individuals and RA patients (cohort I).
We found that the average expression of PTPN22 splice
forms in these samples was similar for RA patients and
controls for PTPN22_v4 and PTPN22-long forms, as
well as for the ratio between the two (Table 2). These
data suggest that proinflammatory conditions, such as
IFNg stimulation, may directly change the transcrip-
tional profile for PTPN22 splice forms and that PBMCs
from healthy individuals are able to produce higher
amounts of PTPN22-long forms.
The influence of major RA risk factors on expression of
PTPN22 splice forms in PBMCs of RA patients
We analyzed the expression data with regard to several
parameters related to the risk of RA or disease activity,
including gender, age at disease onset, rheumatoid factor
(RF) and ACPA status, smoking, the HLA-DRB1 SE,
polymorphisms in the PTPN22 locus, DAS28 at baseline
and type of medication for cohort I.
The HLA-DRB1 SE was found to be moderately asso-
ciated with the expression of PTPN22. As can be seen in
Figure 2, RA patients carrying two copies of the SE had
moderately higher expression of both PTPN22_v4 (P =
0.04) and PTPN22-long forms (P = 0.02) compared to indi-
viduals with no or only one copy. However, the ratio
between expression values of the short and long forms
does not significantly differ in individuals with two copies
of the SE allele in comparison with those with one or no
SE alleles.
The RA risk SNP rs2476601 (PTPN22 R620W) did
not associate with the expression of splice forms in our
study, nor did any other polymorphism in the PTPN22
locus show a consistent association. A list of all tested
SNPs can be found in Table S3 Additional file 2.
Influence of methotrexate on PTPN22 expression
Since most of the RA patients were treated with a spec-
trum of anti-inflammatory drugs and disease-modifying
antirheumatic drugs (DMARDs), we tested how these
influence the expression of PTPN22 mRNA. The direct
effect of pharmacological levels of methotrexate was
investigated in two cell lines and in PBMCs from
healthy donors (Figure 3a,b); as can be seen in the fig-
ures, we found only moderate effects on PTPN22
expression. Additionally, we compared the expression
levels of PTPN22 between RA patients with and without
methotrexate treatment at the time of blood donation
and found no differences (Figure 3c). We also found no
effect of type of other medications on the relative
expression or the ratio of the splice forms (data not
shown).
Expression of PTPN22 splice forms in PBMCs from
multiple sclerosis patients
To control for disease specificity of differential expres-
sion of PTPN22 splice forms, we analyzed independent
collections of mRNA from PBMCs from individuals with
MS. The MS patient group showed significantly higher
expression of PTPN22_v4 compared to the control group
(P = 0.01; same controls and same measurement as for
cohort I) and consequently a lower ratio of splice forms
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Figure 2 Expression of PTPN22 splice forms. (a) The ratio of PTPN22-long forms and PTPN22_v4 for rheumatoid arthritis (RA) patients and
controls in cohort I. (b) Expression of PTPN22_v4 and PTPN22-long forms for RA patients stratified by copies of the shared epitope (SE), 0 or 1
(white boxes) versus 2 (grey boxes). (c) The effect of IFNg ex vivo stimulation on expression ratio.
Table 2 Expression of PTPN22 transcripts in peripheral
blood mononuclear cells from healthy controls and
rheumatoid arthritis patients after stimulation with IFNg
(cohort I)
Median relative quantity values
Control group RA patient group P-value
a
Cohort I
PTPN22_v4 0.71 0.68 NS
PTPN22-long 1.36 1.38 NS
long/v4 1.75 1.87 NS
All values are relative to the average expression of non-induced controls.
aP-
value for comparison of the patient group and control group, Mann-Whitney
test. NS, not significant.
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as for cohort I was used for this analysis.
Discussion
Our major finding in the current study is that the
expression of known splice forms of PTPN22 in PBMCs
is different for RA patients and controls. The difference
between patients and controls was even more pro-
nounced for the ratio of the expression of splice forms,
which may reflect a shift in the balance of products: the
cells from RA patients had less Lyp2 (PTPN22_v4) and
more Lyp1 (as represented by PTPN22-long forms) than
cells from controls. These two splice forms are of spe-
cial interest since it is known that they are translated at
detectable levels [3], as also demonstrated in several cell
lines (Figure S1 in Additional file 1). Our experimental
findings are based on three independent cohorts and are
contrasted by data from a cohort of patients with MS.
We did not find clear evidence of genotypic associa-
tion with PTPN22 expression. The lack of association
may be due to the cross-sectional design of the study or
to non-optimal incubation times for PBMCs or a lack of
statistical power. To test for a statistical difference for
such regulation, we would need more data from indivi-
duals with the minor allele homozygotic state.
The association of PTPN22 expression with the HLA-
DRB1 SE is interesting considering previous findings of
interaction between these two RA risk factors [10,11].
This genetic interaction leads to an non-additive
increase in risk for RA for individuals carrying any of
the SE allele AND the PTPN22 risk allele. When we
compared individuals having both or none of the sus-
ceptibility alleles, however, we did not find a significant
effect on expression of PTPN22 (individuals homozy-
gous or heterozygous for the minor allele of rs2476601
and positive for the SE versus individuals homozygous
for major allele and no SE), but this comparison is also
underpowered.
The observed correlation between the ratio of the splice
forms and disease phenotype may have consequences
since the known corresponding protein variants have pro-
nounced structural differences. According to previous data
[3,12], Lyp2 lacks several consensus sequences described
for Lyp1 and other members of the PEST family of phos-
phatases, PTP-PEST (PTP with PEST domain, genomic
designation PTPN12) and PTP-HSCF (PTP hematopoietic
stem-cell fraction, genomic designation PTPN18). These
differences might hint at a cause of functional divergence
between the Lyp splice forms.
First, all three members of the PTP-PEST family con-
tain a carboxy-terminal homology (CTH) domain, which
is a binding site for CD2-binding protein 1 (CD2BP1), a
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Figure 3 Effect of methotrexate on expression of PTPN22 splice forms. Investigating a possible effect of methotrexate (MTX) treatment. (a,
b) For both cell lines (a) and peripheral blood mononuclear cells (PBMCs) (b), cells were incubated with medium and a range of concentrations
of methotrexate for 24 h followed by quantitative PCR measurement of PTPN22 and cytotoxicity analysis (Figure S2 in Additional file 1). The ratio
of PTPN22_long and PTPN22_v4 is shown in the graphs with standard error. (c) Boxplots showing the distribution in cohort I of the ratio of
PTPN22_long and PTPN22_v4 expression stratified by methotrexate treatment. In cohort I, 23 patients were on methotrexate treatment at the
time of sampling.
Table 3 Expression of PTPN22 transcripts in peripheral
blood mononuclear cells for a cohort of 60 multiple
sclerosis patients (cohort IV)
Median relative quantity values
Control group MS Patient group P-value
a
Cohort IV
PTPN22_v4 1.05 1.36 0.01
PTPN22-long 1.03 0.91 NS
long/v4 1.01 0.68 0.0003
All values are relative to the average expression of non-induced controls.
Controls are from cohort I using the previous measurement. The same
protocol for sample preparation was used as for cohort IV.
aP-value for
comparison of the patient group and control group, Mann-Whitney test. NS,
not significant.
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PEST family [19]. CD2BP1 is expressed in T cells and
has been proposed to be an important regulator of
T-cell behavior by modulating CD2 activity, the latter
being involved with the efficiency with which T-cell
receptors bind a major histocompatibility complex
(MHC) molecule with an antigenic peptide [20,21].
Second, it has also been reported that the carboxyl
terminus of Lyp1 contains a consensus sequence recog-
nized by cyclin-dependent kinase 1 (CDK1), a cell cycle
regulatory kinase, suggesting that phosphorylation of
Lyp1 may be cell cycle-dependent. The short variant of
the protein, Lyp2 (corresponding to PTPN22_v4), lacks
the consensus motif for CDK1, implying altered cell
cycle-related regulation of this transcript in lymphoid
cells compared to Lyp1 [3].
Third, the long variant of the protein, Lyp1, also con-
tains four potential SRC homology 3 (SH3) domain
binding sites, compared with a single motif in Lyp2, sug-
gesting that the proteins may interact with different sets
of SH3 domains [3]. For instance, Lyp2 does not contain
the consensus motif PPPLPERTP, responsible in mice
for binding p50csk (proto-oncogene c-Src in humans),
as demonstrated in hematopoietic cells with both PEP
and PTP-PEST [22,23]. c-Src is known to negatively reg-
ulate leukocyte-specific protein tyrosine kinase - an
important mediator in cytokine production signaling
[24]. In a study where similar proline-rich substrate-
binding motifs were deleted in the carboxyl terminus of
PTP-PEST, it was demonstrated that some of these
motifs are required in order for the phosphatase to be
able to inhibit B-cell activation [25].
It was previously suggested that the R620W variant of
PTPN22 alters the protein-protein interaction with c-Src
tyrosine kinase, CSK, with the subsequent down regula-
tion of lymphocyte-specific protein tyrosine kinase,L c k ,
which is a gain of function of phosphatase [5]. Our data
suggest that the structural background for T-cell activa-
tion could also be due to a shift in the expression of splice
forms. Individuals with RA in the studied cohorts may
generally have more of the longer and putatively more
active PTPN22 transcripts, as represented by measurement
of the 3’ end of long splice forms, while healthy controls in
our study have less. Further investigation is required to
elucidate the disease-associated expression patterns of the
individual long splice forms.
It remains unclear how the risk allele relates to
expression of PTPN22 splice forms, although due to
extensive linkage disequilibrium in the PTPN22 locus,
any regulatory variant for alternative splicing could be
of importance and should be investigated. However, our
search for potential variants of splicing motifs within
the PTPN22 gene did not reveal any clear candidate
SNPs for mechanistic studies.
These possible functional differences between Lyp1
and Lyp2 were underappreciated previously and may
s u g g e s tt h a tas h i f ti nt h eb a l a n c eo fs p l i c ef o r m sc o u l d
have a considerable impact on the inflammatory signal-
ing. This difference in expression seems not to be signif-
icantly regulated by allelic variants and although it
cannot be totally excluded according to our cell line
experiments, the expression seems not to be affected by
medication of the patients. Also, in the presence of a
strong inflammatory environment (IFNg in our study)
the balance in transcript expression could be well com-
pensated. Interestingly, our study of PTPN22 splice form
expression in MS patients did not show a similar effect,
which is in line with the fact that this disease is not
associated with polymorphisms in the PTPN22 gene and
supports disease specificity [2,26-29]. To resolve if this
difference in expression is related to genetic association
with PTPN22 variants, expression of PTPN22 splice
forms in systemic lupus erythematosus and type 1 dia-
betes should be tested in a similar way.
Conclusions
We found important differences in the expression of
PTPN22 splice forms between healthy individuals and
RA patients, which may increase a gain of function that
influences development of the RA.
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